Premium
Membrane‐permeable Bcl‐x L prevents MPTP‐induced dopaminergic neuronal loss in the substantia nigra
Author(s) -
Dietz Gunnar P. H.,
Stockhausen née Peters Kerstin V.,
Dietz Birgit,
Falkenburger Björn H.,
Valbuena Paola,
Opazo Felipe,
Lingor Paul,
Meuer Katrin,
Weishaupt Jochen H.,
Schulz Jörg B.,
Bähr Mathias
Publication year - 2008
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.2007.05028.x
Subject(s) - substantia nigra , pars compacta , mptp , dopaminergic , tyrosine hydroxylase , neurodegeneration , neurotoxin , neuroprotection , programmed cell death , neuroscience , microbiology and biotechnology , bcl xl , apoptosis , biology , dopamine , chemistry , medicine , endocrinology , biochemistry , disease
The anti‐apoptotic Bcl‐x L is a promising agent to prevent neurodegeneration in Parkinson’s disease, which is characterized by a demise of dopaminergic neurons. We linked Bcl‐x L to a peptide that allows its delivery across biological membranes and the blood–brain barrier. We tested the fusion protein in two models of Parkinson’s Disease. Cell‐permeable Bcl‐x L protected neuroblastoma cells from the selective neurotoxin 1‐methyl‐4‐phenylpyridinium. Furthermore, its systemic application in aged mice protected dopaminergic neurons following administration of MPTP as revealed by counting of tyrosine hydroxylase‐immunoreactive neurons in the substantia nigra pars compacta . Hence, we present that a cell‐permeable form of an anti‐apoptotic protein can be delivered to CNS neurons through its systemic application, and we provide the proof that the delivery of this protein to the CNS neurons effectively prevents neuronal cell death in models of chronic neurodegenerative diseases.